Nuwacell Biotechnologies Co., Ltd.
Xiaoyu Zhu, M.D., Ph.D.
A clinical study to Evaluate the Safety and Efficacy of NK cells in the treatment of Myelodysplastic Syndromes
Relapsed / Refractory Myelodysplastic Syndromes
NCR300
Early Phase 1
This is a single arm, open-label, single-center pilot study. In this study, 15 patients will be enrolled. The primary purpose is to explore the safety including incidence of adverse events and serious adverse events.The secondary purpose is to explore the efficacy.
Study Type : | Interventional |
Estimated Enrollment : | 15 participants |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes |
Actual Study Start Date : | May 30, 2022 |
Estimated Primary Completion Date : | May 30, 2025 |
Estimated Study Completion Date : | April 30, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: NK cells |
Drug: NCR300 |
Ages Eligible for Study: | 18 Years to 75 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.